Design Therapeutics plans DT-818 DM1 trial H1 2026; Q3 net loss $17M; cash $206M

Design Therapeutics, Inc.

2025-Q3 EPS reported -$0.95

DT-818 nominated as DM1 development candidate; >90% reduction in toxic RNA foci in preclinical studies.
Ex-US regulatory clearance obtained; Phase 1 MAD trial in Australia to start H1 2026; splicing data expected 2027.
Q3 2025 net loss $17.0M; R&D expense $14.6M; G&A expense $4.7M.
Cash and securities $206.0M as of Sept 30, 2025, supporting pipeline advancement.
Board appointed Justin Gover (former CEO of GW Pharma, led $7B acquisition by Jazz) in September 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.